Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term follow-up of eli-cel treated subjects with cerebral adrenoleukodystrophy
NL-OMON60855Phase 3Active, not recruiting
- Sponsor
- bluebird bio
- Start
- Feb 2022
- Modality
- Cell Therapies, Gene Therapies
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of elivaldogene autotemcel in cerebral adrenoleukodystrophy (CALD), sponsored by bluebird bio. Primary endpoints: Major functional disability-free survival, Malignancies and 4 more. Started Feb 2022; status: active, not recruiting.
02
Drugs
elivaldogene autotemcel
03
Conditions
cerebral adrenoleukodystrophy (CALD)
Beyond the preview
Go deeper on NL-OMON60855.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON60855.